The results appear to surpass those seen with Merck & Co Inc's pill, molnupiravir, which was shown last month to halve the likelihood of dying or being hospitalized for COVID-19 patients also at high ...

Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX), two companies forever linked by their historic COVID-19 vaccine ...

The CHMP’s recommendation will be reviewed by the European Commission (EC), which is expected to make its final decision soon. Pfizer and BioNTech have already initiated manufacturing of the ...

A German court found Wednesday that American pharmaceutical giant Pfizer and German firm BioNTech violated a patent to make their COVID-19 vaccine. Siding with Moderna, an American pharmaceutical firm ...

European regulators have officially approved the latest 2026–2027 COVID-19 vaccine formula from Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX). Designed to protect against the widespread XFG ...

The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1 Shipping of the LP.8.1-adapted vaccine will ...

Pfizer beats earnings forecasts for the second quarter, while BioNTech’s results miss expectations due to weak Covid vaccine demand.

Add Yahoo as a preferred source to see more of our stories on Google. Pfizer Inc. signage is seen on July 22, 2020 in New York City. (Jeenah Moon via Getty Images) This story was originally published ...

Arbutus Biopharma and its licensee Genevant filed three patent infringement lawsuits against Pfizer and BioNTech for its lipid nanoparticle technology. The clinical-stage biopharmaceutical company is ...

Guido Oelkers will inherit a deep cancer pipeline, declining vaccine sales and $19 billion to fund the transition.

Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to ...